Xvivo Perfusion AB

XVIVO · Nasdaq Stockholm · Healthcare

213.60SEK −4.5%last day

Price as of 2 October 2026

The price over the past year, with dividends: +23.3%

Performance

1 month

−19.2%

1 year

+23.3%

3 years, per year

−7.7%

5 years, per year

−11.3%

Largest fall, 3 years

−70.2%

Below the peak now

−60.4%

Volatility, 1 year

48.4%

Return with dividends reinvested.

Key figures

P/E

73.4

P/B

3.0

Dividend yield

0.0%

Return on equity

+4.0%

Net margin

+9.9%

Market value

670 m USD

Quality, value and trend

Where Xvivo Perfusion stands against every Nordic stock today. 100 is best.

Quality69

Profitability and a sound balance sheet over time. Better than 69% of Nordic stocks.

Value18

The price measured against earnings, assets and cash flow. Better than 18% of Nordic stocks.

Trend40

The price development over the past year. Better than 40% of Nordic stocks.

Combined33

Quality, value and trend together. Better than 33% of Nordic stocks.

About Xvivo Perfusion

Xvivo Perfusion AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 200 employees.

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entir…

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis